Aptose Biosciences (TSE:APS) Sets New 52-Week High – Here’s What Happened

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) reached a new 52-week high during trading on Thursday . The company traded as high as C$2.40 and last traded at C$2.40, with a volume of 28032 shares traded. The stock had previously closed at C$2.14.

Aptose Biosciences Stock Up 12.1%

The firm has a market capitalization of C$6.12 million, a PE ratio of -0.23 and a beta of -1.38. The firm’s 50 day moving average price is C$2.26 and its two-hundred day moving average price is C$2.23. The company has a quick ratio of 5.41, a current ratio of 0.55 and a debt-to-equity ratio of -98.74.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported C($4.16) earnings per share for the quarter. As a group, research analysts forecast that Aptose Biosciences Inc. will post -0.59 EPS for the current fiscal year.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.